Ibuprofen IV vs Acetaminophen IV for the Treatment of Pain Following Orthopaedic Low Extremity Surgery

Sponsor
Indonesia University (Other)
Overall Status
Completed
CT.gov ID
NCT03771755
Collaborator
(none)
62
1
2
5
12.4

Study Details

Study Description

Brief Summary

This study aims to evaluate the efficacy of IV Ibuprofen versus IV Acetaminophen in the reduction of pain following orthopedic low extremity procedures

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

Approval from Ethical Committee of Faculty of Medicine Universitas Indonesia was acquired prior conducting the study. Patients undergoing orthopedic low extremity surgery were screened. Eligible subjects were then randomized into treatment group (intravenous ibuprofen) and control group (intravenous acetaminophen). In case required, patients from both group will be given Morphine (PCA) 1-2 mg every 5 minutes.

Study Design

Study Type:
Interventional
Actual Enrollment :
62 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Supportive Care
Official Title:
A Prospective, Randomized, Double-blind Study Assessing the Efficacy of Intravenous (IV) Ibuprofen Versus IV Acetaminophen for the Treatment of Pain Following Orthopaedic Low Extremity Surgery
Actual Study Start Date :
Jul 1, 2017
Actual Primary Completion Date :
Nov 30, 2017
Actual Study Completion Date :
Nov 30, 2017

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Ibuprofen group

800 mg IV - Ibuprofen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes

Drug: Ibuprofen
800 mg IV - Ibuprofen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes

Placebo Comparator: Acetaminophen group

1000mg IV Acetaminophen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes

Drug: Acetaminophen
1000mg IV Acetaminophen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes

Outcome Measures

Primary Outcome Measures

  1. Pain intensity [24 hours]

    demonstrated by the measurement VAS (Visual Analog Scale) for 24 hrs postoperative.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Scheduled for Orthopedic Low Extremity Surgery with general anesthesia and anticipated need post operative IV analgesia with anticipated use of >48 hours.

  • Adequate IV access.

  • Anticipated hospital stay>48 hours.

  • Age 18-70 years old with physical status ASA I- III.

  • Patients able to fill informed consent sheet.

Exclusion Criteria:
  • patients with use of analgesia, muscle relaxants, NSAIDs and sedatives less than 24 hours to study drug administration

  • anemia (active, clinically significant anemia) and/or a history or evidence of asthma or heart failure

  • historical or at higher risk intracerebral bleeding, history of allergy or hypersensitive to NSAID, Ibuprofen, Acetaminophen or opioid

  • pregnant or nursing

  • body weight less than 30 kg

  • any active clinically significant bleeding or have underlying platelet dysfunction and/or receiving full dose anticoagulation therapy

  • GI bleeding that required medical intervention within the previous 6 weeks (unless definitive surgery has been performed)

  • on dialysis or renal dysfunction

  • impaired liver function

  • inability to achieve hemostasis or inability to close surgical incision prior to operating room discharge

  • operative procedure includes organ transplant, pre-and intra- operative procedure utilized for the prevention of pre- or post-operative pain (i.e, epidural or nerve blocks)

  • received anoher investigational drug within the past 30 days

  • known or suspected history of alcohol or drug abuse

  • severe infection and/or inflammatory disease

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cipto Mangunkusumo Cental National Hospital Jakarta DKI Jakarta Indonesia 10430

Sponsors and Collaborators

  • Indonesia University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Aida Rosita Tantri, Principal Investigator, Indonesia University
ClinicalTrials.gov Identifier:
NCT03771755
Other Study ID Numbers:
  • IndonesiaUAnes026
First Posted:
Dec 11, 2018
Last Update Posted:
Aug 20, 2020
Last Verified:
Aug 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Aida Rosita Tantri, Principal Investigator, Indonesia University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 20, 2020